Edition:
United Kingdom

Celsion Corp (CLSN.OQ)

CLSN.OQ on NASDAQ Stock Exchange Capital Market

2.83USD
18 Sep 2018
Change (% chg)

$0.06 (+2.17%)
Prev Close
$2.77
Open
$2.77
Day's High
$2.84
Day's Low
$2.77
Volume
23,628
Avg. Vol
34,080
52-wk High
$6.06
52-wk Low
$1.46

Chart for

About

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall... (more)

Overall

Beta: 0.88
Market Cap(Mil.): $27.98
Shares Outstanding(Mil.): 8.35
Dividend: --
Yield (%): --

Financials

  CLSN.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -8.37 -- --
ROI: -78.33 1.78 14.61
ROE: -191.72 3.29 16.33

BRIEF-Celsion Phase III Clinical Study Of Thermodox In Combination With Radiofrequency Ablation To Continue According To Protocol

* PHASE III CLINICAL STUDY OF THERMODOX IN COMBINATION WITH RADIOFREQUENCY ABLATION TO CONTINUE ACCORDING TO PROTOCOL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

09 Apr 2018

Earnings vs. Estimates